Circulating Nephrin Antibodies and Post-Transplant Recurrence of Diffuse Podocytopathies: A Systematic Review
- 1Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, MN.
Abstract
Recurrence of diffuse podocytopathy (DP), primarily focal segmental glomerulosclerosis and minimal change disease, after kidney transplantation threatens allograft survival. Circulating nephrin autoantibodies have been linked to disease activity, but posttransplant evidence remains limited. We performed a systematic review with patient-level data extraction, including kidney transplant recipients with DP as their native kidney disease from studies reporting serum nephrin antibody testing and posttransplant outcomes. Four studies including 63 recipients (23 pediatric and 40 adult) with DP were included, comprising 53 focal segmental glomerulosclerosis, 8 minimal change disease, and 2 steroid-resistant nephrotic syndrome cases. Nephrin antibodies were detected in 22 of 62 tested recipients (36%), either before transplantation or during posttransplant recurrence, including one patient in whom antibodies were detected 9 years after transplantation. Recurrence occurred in 34 of 63 recipients (54%), including 20 of 22 (91%) antibody-positive patients. Antibody positivity was strongly associated with recurrence (OR 20.8; 95% CI, 4.2-102.6; P < 0.001), with sensitivity of 61%, specificity of 93%, positive predictive value of 91%, and negative predictive value of 68%. Antibody titers correlated with disease activity and declined with remission. Nephrin autoantibodies are associated with posttransplant recurrence of DP and may inform pretransplant risk stratification and posttransplant monitoring. Standardized assays and larger validation studies are needed.
Related
- Circulating anti-Ro/Sjögren’s syndrome-related antigen A antibodies and risk of heart rate-corrected QT interval prolongation: a meta-analysis
- Sensitive Glioma Detection and Recurrence Monitoring Using a Machine Learning Model Based on Circulating Monocytes
- From epithelial-mesenchymal transition to liquid biopsy: mechanisms of gastric cancer metastatic dissemination and circulating biomarker-guided anti-recurrence strategies
- Longitudinal Circulating Nerve Growth Factor in Pancreatic Ductal Adenocarcinoma: An Exploratory Study of Postoperative Recurrence and First-Line Disease Control
- Whole-genome sequencing-based tumor-informed circulating tumor DNA monitoring for early detection of recurrence in patients with solid tumors
BibTeX
@article{aiumtrakul2026circulating,
title = {{Circulating Nephrin Antibodies and Post-Transplant Recurrence of Diffuse Podocytopathies: A Systematic Review}},
author = {Noppawit Aiumtrakul and Charat Thongprayoon and Jing Miao and Wisit Cheungpasitporn},
journal = {Kidney medicine},
year = {2026},
month = sep,
doi = {10.1016/j.xkme.2026.101521},
url = {https://europepmc.org/article/PMC/PMC13717021},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Circulating Nephrin Antibodies and Post-Transplant Recurrence of Diffuse Podocytopathies: A Systematic Review
AU - Noppawit Aiumtrakul
AU - Charat Thongprayoon
AU - Jing Miao
AU - Wisit Cheungpasitporn
PY - 2026
DA - 2026/09/09
JO - Kidney medicine
DO - 10.1016/j.xkme.2026.101521
UR - https://europepmc.org/article/PMC/PMC13717021
AB - Recurrence of diffuse podocytopathy (DP), primarily focal segmental glomerulosclerosis and minimal change disease, after kidney transplantation threatens allograft survival. Circulating nephrin autoantibodies have been linked to disease activity, but posttransplant evidence remains limited. We performed a systematic review with patient-level data extraction, including kidney transplant recipients with DP as their native kidney disease from studies reporting serum nephrin antibody testing and posttransplant outcomes. Four studies including 63 recipients (23 pediatric and 40 adult) with DP were included, comprising 53 focal segmental glomerulosclerosis, 8 minimal change disease, and 2 steroid-resistant nephrotic syndrome cases. Nephrin antibodies were detected in 22 of 62 tested recipients (36%), either before transplantation or during posttransplant recurrence, including one patient in whom antibodies were detected 9 years after transplantation. Recurrence occurred in 34 of 63 recipients (54%), including 20 of 22 (91%) antibody-positive patients. Antibody positivity was strongly associated with recurrence (OR 20.8; 95% CI, 4.2-102.6; P < 0.001), with sensitivity of 61%, specificity of 93%, positive predictive value of 91%, and negative predictive value of 68%. Antibody titers correlated with disease activity and declined with remission. Nephrin autoantibodies are associated with posttransplant recurrence of DP and may inform pretransplant risk stratification and posttransplant monitoring. Standardized assays and larger validation studies are needed.
SN - 2590-0595
ER -